Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sten Stovall

London, UK
Sten Stovall is a London-based editor and writer with 40 years of experience in the field of journalism, including more than 20 years with Reuters and eight years with The Wall Street Journal/Dow Jones Newswires. He also has wide radio and television reporting experience and a solid network of contacts in the biopharma world. Sten is part of our team of specialist reporters, generating insightful features and analysis about R&D, product development, regulatory issues and industry trends for publications such as "The Pink Sheet", Scrip and IN VIVO.
Set Alert for Articles By Sten Stovall

Latest From Sten Stovall

Semaglutide's CHMP Backing Stipulates Post-Approval Safety Studies

Novo Nordisk's once-weekly diabetes treatment semaglutide wins backing from EMA's top advisory panel one week after the GLP-1 agonist was approved in the US, the first country to do so. Safety studies have been required.

Approvals Drug Safety

Newly Launched Peptide Specialist Aelin Therapeutics Seeks CEO

Flemish academic spin-off Aelin Therapeutics harnesses the power of protein aggregation to specifically induce functional neutralization or 'knockdown' of a target protein.

Business Strategies Commercial

Arix Shepherds Atox $30m Funding Amid High Hopes For Start-up's Lead Asset

Its investment in Atox Bio's $30m Series F financing round added the 12th company to Arix's portfolio, hitting a target set at its February IPO. Atox’s late-stage peptide is designed to modulate a patient’s response to severe infections.

Business Strategies Clinical Trials

RWE and Clinical Trials To Take Center Stage In UK Sector Deal Prospects

Some of the loudest messages from UK government's Life Science Sector Deal was the importance of using real world evidence - and the uniqueness the British health ecosystem can offer to trail blazing innovation.

Brexit Business Strategies

Sir John Bell: UK Life Science Pact Essential For Post-Brexit Success

Successfully piecing together the agreed life sciences sector deal calls for the UK to embrace high-risk innovation and placing the NHS at its center, says Sir John Bell who helped formulate the pact.

Brexit Business Strategies

BeyondSpring CEO: China's New System Will Get Our Drug To Market Faster

The US/Chinese biotech expects speedier approval of its lead asset plinabulin in China thanks to the government's new drug approval policy.

Business Strategies Clinical Trials
See All